JAC Advance Access originally published online on March 13, 2007
Journal of Antimicrobial Chemotherapy 2007 59(5):1013-1016; doi:10.1093/jac/dkm067
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Emergence of the H208Y mutation in the reverse transcriptase (RT) of HIV-1 in association with nucleoside RT inhibitor therapy
1 Department of Virology, Royal Free and University College Medical School, Rowland Hill Street, NW3 2PF London, UK 2 Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Rowland Hill Street, NW3 2PF London, UK 3 Medical Research Council, Clinical Trial Unit, London, UK
Received 27 November 2006; returned 22 January 2007; revised 24 January 2007; accepted 13 February 2007
* Corresponding author. Tel: +44-207-3177521; Fax: +44-207-8302854; E-mail: ea.geretti{at}medsch.ucl.ac.uk
Objectives: The aim of the study was to determine whether mutations at RT codon 208 are associated with nucleoside RT inhibitor (NRTI) exposure, NRTI resistance patterns and HIV-1 subtype.
Methods: Six thousand three hundred and fifty two genotypic resistance tests linked to a clinical database were analysed.
Results: The prevalence of mutations at codon 208 was 6/2347 (0.3%) in treatment-naive and 165/4005 (4.1%) in treatment-experienced persons. H208Y was the most common mutation in both groups (0.2% and 3.8%, respectively) and occurred in 4.5% of treatment-experienced persons with Subtype B, 1.7% of those with Subtype C and 0.7% of those with other non-B subtypes (P = 0.001). The association with subtypes was independent of treatment experience. H208Y showed a strong association with NRTI experience, which persisted after adjusting for subtype [odds ratio (OR) 19.34; 95% confidence interval (CI) 7.87–47.54; P = 0.0001]. The prevalence of H208Y was highest in genotypes harbouring M184V and the thymidine analogue mutations (TAMs) M41L, D67N, L210W and T215Y. The median number of TAMs was 4 and 0 in genotypes with and without H208Y, respectively (P = 0.0001). The prevalence of H208Y declined over time, being highest in 1998 (9.9%) and lowest in 2003 (0.9%) (P = 0.0001).
Conclusions: There is a strong association between H208Y and NRTI experience, particularly in persons with Subtype B harbouring multiple NRTI resistance mutations. These findings indicate an accessory role for H208Y in NRTI resistance.
Keywords: resistance , mutations , lamivudine
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Garriga, M. J. Perez-Elias, R. Delgado, L. Ruiz, L. Perez-Alvarez, T. Pumarola, A. Lopez-Lirola, J. Gonzalez-Garcia, L. Menendez-Arias, and on behalf of the Spanish Group for the Study of An HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with virological failure to nucleoside drug combinations J. Antimicrob. Chemother., August 1, 2009; 64(2): 251 - 258. [Abstract] [Full Text] [PDF]
|
|